Efficacy and safety of 3‐month dosing regimen of degarelix in Japanese subjects with prostate cancer: A phase III study

Non‐inferiority in the cumulative castration rate of the 3‐month formulation of degarelix compared with the 3‐month formulation of goserelin was evaluated in subjects with prostate cancer. A phase III, open‐label, parallel‐arm study was carried out. An initial dose of 240 mg degarelix or 3.6 mg gose...

Descripción completa

Detalles Bibliográficos
Autores principales: Ozono, Seiichiro, Tsukamoto, Taiji, Naito, Seiji, Horie, Shigeo, Ohashi, Yasuo, Uemura, Hiroji, Yokomizo, Yumiko, Fukasawa, Satoshi, Kusuoka, Hidehito, Akazawa, Rio, Saito, Masako, Akaza, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989846/
https://www.ncbi.nlm.nih.gov/pubmed/29624800
http://dx.doi.org/10.1111/cas.13600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989846/
https://www.ncbi.nlm.nih.gov/pubmed/29624800
http://dx.doi.org/10.1111/cas.13600

Ejemplares similares